A new family office fund of a successful hedge fund manager focused on private investments has multiple offices in the US. Due to the single LP structure of the fund, it can be very flexible in terms of investment size and stage. The firm is open to working with companies in the seed, series A, and series B stage with the majority of investments falling in the $500k-2.5M range. The firm also has the ability to allocate $5M or more in situations where they find the opportunity particularly compelling. The firm is capable of both acting as a lead and co-investor, and is primarily focused on companies throughout North America but has exposure to Europe and Asia as well.
The firm has a focus on vertically integrated platforms and software/”software x hardware” systems. Specifically, the firm is interested in AI-enabled drug discovery platforms, lab automation, diagnostics and data collection, and clinical trials management software. The firm is generally agnostic in terms of both stage of development and indication area but is most interested in early stage, highly innovative biotech companies.
The firm is looking for privately held companies with experienced management teams and a product/service with a large addressable market.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Family Office Fund Invests in North American Companies in the Intersection of Technology of Life Science, Such as AI-Enabled Drug Discovery Platforms
24 AugAnnouncing Family Office BioForum at RESI Boston September 2023
17 AugBy Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
RESI Boston September will feature the Family Office BioForum, for both sourcing assets and identifying syndication partners bridging the gap between family offices and investment opportunities within the life sciences sector. The Family Office BioForum will feature an open-to-the-public Family Office Panel as part of the RESI program and an invitation-only luncheon discussing early-stage investment topics, including souring technology assets, identifying syndicate opportunities, and finding the right investment funds.
As the life sciences sector continues to burgeon with groundbreaking discoveries, therapies, and technologies, the need for early capital injection becomes ever more pronounced. The Family Office BioForum is a convergence point where family offices can simultaneously identify promising startups and collaborate with other like-minded investors.
The Power of Syndication
Syndication has emerged as a dynamic strategy in the investment landscape, offering distinct advantages to family offices and entrepreneurs seeking funding. Family offices can diversify risk and share due diligence efforts by joining forces with other investors in a syndicate. This collaborative approach allows investors to tap into a broader range of investment opportunities and capitalize on their combined expertise. Conversely, entrepreneurs benefit from access to a syndicate’s collective knowledge and resources, expediting fundraising and enhancing their chances of securing the necessary funds.
The Family Office Factor
Family offices are known for their long-term investment outlook and commitment to fostering meaningful impact. With a mission to preserve and grow their wealth across generations, family offices are uniquely positioned to contribute to the life sciences sector. Their involvement goes beyond monetary support; it encompasses mentorship, guidance, and a vested interest in the success of the ventures they invest in. The Global Family Office BioForum acknowledges this distinctive role and seeks to create an environment where family offices can connect with like-minded syndicate partners and explore transformative investment opportunities.
| For more information on the Family Office BioForum | Click here |
| If you are a Family Office and would like to attend the Family Office BioForum Luncheon | Click here |
Partnering Opens for RESI Boston Next Week
17 AugBy Karen Deyo, Director of Product, Israel BD, LSN
Partnering for RESI Boston September, a hybrid event (in-person on September 18, or virtually on September 19-20) launches next Monday, giving registered attendees access to RESI’s unique partnering platform. This platform allows attendees to filter search results with a high degree of precision.
At RESI, unlike other conferences, requesting a meeting with an investor does not require a company to spend most of the initial meeting finding out if they are a fit for the investor or not. Companies can easily determine a list of investors who are interested in their sector, indication, and stage of development before requesting a meeting. Investor profiles are written by Life Science Nation (LSN)’s Investor Research team in a phone interview with each investor, as a requirement before registration.
The RESI Partnering Platform has an integrated video conferencing system, allowing companies to simply log in to the platform and initiate their meetings through their schedule. Make sure to look at the tutorial video below, to see all the features offered by our system!
Premier Platform Sample
Sign up for our free partnering tutorials below and register for RESI before partnering opens to have as much time as possible to maximize your partnering experience!
LSN Announces Collaboration with Government of Ontario and Ontario Bioscience Innovation Organization (OBIO) at RESI Boston in September
17 AugBy Erika Wu, Business Development Manager, Global Tech Hubs, LSN
Life Science Nation (LSN) is thrilled to be collaborating with the Government of Ontario and Ontario Bioscience Innovation Organization (OBIO) at the Redefining Early Stage Investments (RESI) conference, scheduled to take place from September 18-20 at the Boston Park Plaza. The first day will consist of in-person partnering, panels, pitches, and workshops, followed by two virtual partnering days. This collaboration brings together three influential organizations who are tackling the life sciences arena and aims to foster an ecosystem where innovation is nurtured and capital flows seamlessly in Ontario, Canada.
As part of this collaboration, the Government of Ontario and OBIO will be featuring a group of 15 early-stage startups to showcase the latest advancements across:
- Nutrition
- Polyphenols to treat chronic diseases
- Robotic intramuscular injections
- Wearable artificial kidney for ambulatory dialysis
- Therapies and solutions in HDAC-driven pathologies, surgical oncology, complex inflammatory skin diseases, and onychomycosis
- Electronic medical records
- Non-viral and re-dosable gene therapies
These entrepreneurs will be provided with a unique platform to present their disruptive technologies, engage in one-on-one discussions with potential investors seeking to catalyze growth and expedite the journey toward impactful biotechnological breakthroughs.
With their unique and collaborative innovation ecosystem, Ontario is where companies come to grow and prosper. The same innovative spirit that led to the discovery of insulin in Ontario one hundred years ago has led to game-changing technologies such as 3D bioprinters and techniques to boost stem cell renewal. Whether you want to expand your operations here or source some of the highest quality medical products and services in the world, Ontario is your life sciences destination.
Get ready to meet the 15 startups and staff from Government of Ontario and OBIO at RESI Boston in September!
Hot Investor Mandate: USA-Based Investment Firm Makes Both Venture & Growth Stage Investments, Focusing Exclusively on Therapeutics
17 AugFrazier Healthcare Ventures was founded in 1991 and is based in Seattle, WA. The firm has $2.2 billion of assets under management, and closed a new $525 million fund in 2016. Frazier currently has two investment strategies; growth-stage investments in healthcare and pharma service providers (these investments focus on companies with $5-30m EBITDA), and venture-stage investments in life science companies. Frazier’s venture allocations have initial sizes of $5m or higher, with the potential for allocations of up to $20m over the life of an investment. While Frazier primarily invests in companies based in or with significant operations in the USA and/or Canada, the firm will also consider opportunities in Europe. In addition to growth and venture-stage investments, Frazier also engages in company creation. The firm is a lead investor in most of its deals.
Frazier Life Sciences only invests in therapeutics, with a focus on asset-based companies. Frazier typically prefers to invest in companies with products which are 6-18 months away from bringing a product candidate into Phase I clinical trials, but may consider investing in assets that are earlier or later than that. The firm invests in all therapeutic areas and all modalities.
Frazier Healthcare Ventures has no fixed requirements for companies or management teams, but looks for strong teams that lead companies that can make use of over $10m in capital; companies with smaller capital needs are not of interest. Frazier can invest in both privately-held and public life science companies.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Early-Stage Venture Fund Managed By Top VC Firms Seeks Novel, Disruptive Medtech and Digital Health Companies in USA & Europe
17 AugA newly established, early-stage venture fund backed by a sole strategic LP and managed by leading VC firms is actively seeking new investment opportunities. The LP’s decision to invest in the fund reflects the company’s vision of developing disruptive, cost-saving healthcare solutions, which closely matches the vision of the investment team. The firm focuses on US, Europe, and Israel-based companies.
The firm is dedicated to early-stage investing in novel, disruptive medtech and digital health companies that can transform hospital care to lower-cost settings such as the home and health clinics. Areas of particular interest include non-invasive therapeutic medical devices, monitoring technologies for effective chronic disease management and preventative technologies, and is open to devices of all regulatory pathways.
The firm is looking for technologies supported by strong clinical hypotheses that can cost-effectively address large problems in the current healthcare system. The firm is open to working with all kinds of management teams in the US, Europe or Israel. The firm has access to an international network and resources that can be leveraged to support company growth.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: USA-Based VC Actively Invests in Novel Therapeutic Assets Starting from Late Pre-Clinical Stage, Opportunistic Towards Indication
17 AugA life sciences venture capital firm based in the US is focused on early and growth-stage biotech and pharma companies. The firm has more than $350M assets under management. Initial investments typically range from $2M-$20M and are usually in the form of equity, but may use convertible notes in select situations. The firm looks to take a meaningful stake in portfolio companies and play an active role in their development. The firm is open to companies based in the U.S., with a specific interest in companies located outside of the major biotech hubs of Boston and San Francisco.
The firm focuses on therapeutic companies within the biotech sector. The firm is mostly opportunistic in terms of technology type and indication area; however, the group prioritizes companies developing assets with unique mechanisms of action that address unmet medical needs. The firm typically invests in companies ranging from late preclinical to Phase 2 clinical trials stage. The firm does NOT invest in diagnostic, device, digital health, or healthcare IT companies.
The firm has no strict company or management team requirements, but usually requires a board seat along with an investment to allow for active participation and collaboration with the company during development.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Subscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 